FDA Approves CAPECITABINE — BluePoint Laboratories

BluePoint Laboratories announced the approval of oral capitolabine trading on Wednesday, adding a generic alternative to the market for cancer treatment. The entry is expected to spur competition against brand-name capitolabine, potentially pressuring pricing for oncologists and patients.